Odrik (Trandolapril)

Trandolapril, the active ingredient in Odrik, is an angiotensin‑converting enzyme (ACE) inhibitor presented as an oral dosage form for oral use. It is indicated for the management of hypertension and heart failure in adult patients.

GNH USA supplies Odrik as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality‑assured manufacturing and regulatory compliance across EU and global markets, offering reliable logistics, comprehensive documentation, and responsive technical support throughout the supply chain.

Trandolapril, an ACE inhibitor, is used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers elevated blood pressure by reducing systemic vascular resistance. - Heart failure: improves cardiac output and alleviates symptoms of fluid overload. - Post‑myocardial infarction: helps prevent ventricular remodeling and reduces subsequent cardiovascular risk.

Common Side Effects: - Cough: a dry, persistent cough in some patients. - Dizziness: often related to lowered blood pressure. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Hyperkalemia: elevated serum potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure, especially after the first dose. - Acute renal impairment: sudden decrease in kidney function. - Neutropenia: significant reduction in white blood cells. - Hepatic dysfunction: abnormal liver enzyme elevations.

Trandolapril should be used with caution and under medical supervision. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor to detect hyperkalemia, especially when combined with potassium‑sparing agents. - Aortic stenosis: avoid rapid dose escalation in patients with severe narrowing. - Pregnancy: contraindicated unless clearly needed; discuss risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Trandolapril may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalemia. - Lithium: may raise lithium levels, leading to toxicity. - Potassium‑sparing diuretics (e.g., spironolactone): heightened risk of hyperkalemia. - NSAIDs (high dose): can impair renal function and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect; monitor for hypotension. - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments. - NSAIDs (low dose): may modestly affect renal clearance; monitor renal parameters.